Inovio Pharmaceuticals, Inc.
INO
$2.05
$0.105.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 13.92% | -- | -55.40% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 13.92% | -- | -55.40% | -- |
| Cost of Revenue | -23.06% | -25.32% | 20.84% | 6.12% | -30.70% |
| Gross Profit | 23.37% | 25.55% | -23.94% | -6.76% | 30.43% |
| SG&A Expenses | -14.63% | 37.12% | -13.21% | -24.52% | -17.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.23% | -10.13% | 7.55% | -5.63% | -26.72% |
| Operating Income | 20.44% | 10.24% | -9.22% | 5.31% | 26.53% |
| Income Before Tax | 35.36% | 22.48% | 25.83% | 9.28% | 25.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.36% | 22.48% | 25.83% | 9.28% | 25.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.36% | 22.48% | 25.83% | 9.28% | 25.04% |
| EBIT | 20.44% | 10.24% | -9.22% | 5.31% | 26.53% |
| EBITDA | 20.54% | 9.81% | -10.37% | 4.62% | 26.16% |
| EPS Basic | 61.02% | 41.24% | 41.00% | 26.52% | 30.69% |
| Normalized Basic EPS | 60.49% | 32.32% | 11.16% | 20.87% | 30.64% |
| EPS Diluted | 61.02% | 41.24% | 41.00% | 26.22% | 30.78% |
| Normalized Diluted EPS | 60.49% | 32.32% | 11.16% | 20.87% | 30.64% |
| Average Basic Shares Outstanding | 65.78% | 31.93% | 25.71% | 23.46% | 8.15% |
| Average Diluted Shares Outstanding | 65.78% | 31.93% | 25.71% | 23.46% | 8.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |